Reply

Journal of the American College of Cardiology

Volumn 51, Issue 4, 2008, Pages 517-518

  Messerli, Franz H ^a   Bangalore, Sripal ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NEBIVOLOL; TRANDOLAPRIL PLUS VERAPAMIL;

AORTA PRESSURE; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; CLINICAL RESEARCH; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG USE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LETTER; PRESCRIPTION; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 38349084752     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.10.022     Document Type: Letter

References (7)

1. Bangalore S., Messerli F., Kostis J., and Pepine C. Cardiovascular protection using beta-blockers. A critical review of the evidence. J Am Coll Cardiol 50 (2007) 563-572
2. Wiysonge C.S., Bradley H., Mayosi B.M., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev (2007) CD002003
3. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
4. Messerli F.H., and Grossman E. β-blockers in hypertension: is carvedilol different?. Am J Cardiol 93 Suppl (2004) 7B-12B
5. Messerli F.H., Bell D.S., Fonseca V., et al. Body weight changes with beta-blocker use: results from GEMINI. Am J Med 120 (2007) 610-615
6. Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 24 (1993) 543-548
7. Bangalore S., Parkar S., Grossman E., and Messerli F. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100 (2007) 1254-1262